Retrovirus-based pseudotyped virus neutralisation assays overestimate neutralising activity in sera from participants receiving integrase inhibitors
Retroviral pseudotype-based virus neutralisation assays are widely used to estimate functional immunity, but may be unsuitable for testing human immunodeficiency virus (HIV)-infected individuals receiving integrase inhibitor treatment. We evaluated these assays for measuring severe acute respiratory...
Saved in:
| Published in | Scientific reports Vol. 15; no. 1; pp. 28580 - 13 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
05.08.2025
Nature Publishing Group Nature Portfolio |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2045-2322 2045-2322 |
| DOI | 10.1038/s41598-025-11362-7 |
Cover
| Abstract | Retroviral pseudotype-based virus neutralisation assays are widely used to estimate functional immunity, but may be unsuitable for testing human immunodeficiency virus (HIV)-infected individuals receiving integrase inhibitor treatment. We evaluated these assays for measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus (HCV) neutralisation in people living with HIV. SARS-CoV-2 neutralisation was assessed using HIV-based SARS-CoV-2 pseudoviruses in sera from a longitudinal Malawian cohort (
n
= 1,876), detecting neutralisation across timepoints in 10.5–54.5% of HIV-uninfected vs. 85.5–93.9% of HIV-infected participants (
n
= 96). HIV-infected sera were re-tested using vesicular stomatitis virus (VSV)-based SARS-CoV-2 pseudoviruses, estimating seroprevalence at 5.6–65.2%, suggesting HIV-based assays overestimate neutralisation. HIV-based VSV-glycoprotein(G) pseudoviruses confirmed non-specific inhibition in 75.0-87.9% of HIV-infected participants. HCV neutralisation was assessed in UK-based HCV patients (
n
= 100,
n
= 90 HIV-infected) using murine leukaemia virus (MLV)-based HCV pseudoviruses. Non-HCV-specific inhibition was detected in integrase inhibitor recipients. Median neutralisation of MLV(HCV) pseudoviruses was higher in integrase inhibitor recipients (71.8% vs. 21.3%). Testing HIV(SARS-CoV-2) and MLV(HCV) pseudoviruses against antiretroviral drugs showed interference by integrase inhibitors (specifically, dolutegravir). Isolating IgG from serum removed the interference by residual drugs. Retrovirus-based assays are therefore unsuitable for testing individuals receiving integrase inhibitors. Protective immunity to viruses has likely been over-reported in HIV prevalent populations. |
|---|---|
| AbstractList | Retroviral pseudotype-based virus neutralisation assays are widely used to estimate functional immunity, but may be unsuitable for testing human immunodeficiency virus (HIV)-infected individuals receiving integrase inhibitor treatment. We evaluated these assays for measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus (HCV) neutralisation in people living with HIV. SARS-CoV-2 neutralisation was assessed using HIV-based SARS-CoV-2 pseudoviruses in sera from a longitudinal Malawian cohort (n = 1,876), detecting neutralisation across timepoints in 10.5-54.5% of HIV-uninfected vs. 85.5-93.9% of HIV-infected participants (n = 96). HIV-infected sera were re-tested using vesicular stomatitis virus (VSV)-based SARS-CoV-2 pseudoviruses, estimating seroprevalence at 5.6-65.2%, suggesting HIV-based assays overestimate neutralisation. HIV-based VSV-glycoprotein(G) pseudoviruses confirmed non-specific inhibition in 75.0-87.9% of HIV-infected participants. HCV neutralisation was assessed in UK-based HCV patients (n = 100, n = 90 HIV-infected) using murine leukaemia virus (MLV)-based HCV pseudoviruses. Non-HCV-specific inhibition was detected in integrase inhibitor recipients. Median neutralisation of MLV(HCV) pseudoviruses was higher in integrase inhibitor recipients (71.8% vs. 21.3%). Testing HIV(SARS-CoV-2) and MLV(HCV) pseudoviruses against antiretroviral drugs showed interference by integrase inhibitors (specifically, dolutegravir). Isolating IgG from serum removed the interference by residual drugs. Retrovirus-based assays are therefore unsuitable for testing individuals receiving integrase inhibitors. Protective immunity to viruses has likely been over-reported in HIV prevalent populations.Retroviral pseudotype-based virus neutralisation assays are widely used to estimate functional immunity, but may be unsuitable for testing human immunodeficiency virus (HIV)-infected individuals receiving integrase inhibitor treatment. We evaluated these assays for measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus (HCV) neutralisation in people living with HIV. SARS-CoV-2 neutralisation was assessed using HIV-based SARS-CoV-2 pseudoviruses in sera from a longitudinal Malawian cohort (n = 1,876), detecting neutralisation across timepoints in 10.5-54.5% of HIV-uninfected vs. 85.5-93.9% of HIV-infected participants (n = 96). HIV-infected sera were re-tested using vesicular stomatitis virus (VSV)-based SARS-CoV-2 pseudoviruses, estimating seroprevalence at 5.6-65.2%, suggesting HIV-based assays overestimate neutralisation. HIV-based VSV-glycoprotein(G) pseudoviruses confirmed non-specific inhibition in 75.0-87.9% of HIV-infected participants. HCV neutralisation was assessed in UK-based HCV patients (n = 100, n = 90 HIV-infected) using murine leukaemia virus (MLV)-based HCV pseudoviruses. Non-HCV-specific inhibition was detected in integrase inhibitor recipients. Median neutralisation of MLV(HCV) pseudoviruses was higher in integrase inhibitor recipients (71.8% vs. 21.3%). Testing HIV(SARS-CoV-2) and MLV(HCV) pseudoviruses against antiretroviral drugs showed interference by integrase inhibitors (specifically, dolutegravir). Isolating IgG from serum removed the interference by residual drugs. Retrovirus-based assays are therefore unsuitable for testing individuals receiving integrase inhibitors. Protective immunity to viruses has likely been over-reported in HIV prevalent populations. Retroviral pseudotype-based virus neutralisation assays are widely used to estimate functional immunity, but may be unsuitable for testing human immunodeficiency virus (HIV)-infected individuals receiving integrase inhibitor treatment. We evaluated these assays for measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus (HCV) neutralisation in people living with HIV. SARS-CoV-2 neutralisation was assessed using HIV-based SARS-CoV-2 pseudoviruses in sera from a longitudinal Malawian cohort ( n = 1,876), detecting neutralisation across timepoints in 10.5–54.5% of HIV-uninfected vs. 85.5–93.9% of HIV-infected participants ( n = 96). HIV-infected sera were re-tested using vesicular stomatitis virus (VSV)-based SARS-CoV-2 pseudoviruses, estimating seroprevalence at 5.6–65.2%, suggesting HIV-based assays overestimate neutralisation. HIV-based VSV-glycoprotein(G) pseudoviruses confirmed non-specific inhibition in 75.0-87.9% of HIV-infected participants. HCV neutralisation was assessed in UK-based HCV patients ( n = 100, n = 90 HIV-infected) using murine leukaemia virus (MLV)-based HCV pseudoviruses. Non-HCV-specific inhibition was detected in integrase inhibitor recipients. Median neutralisation of MLV(HCV) pseudoviruses was higher in integrase inhibitor recipients (71.8% vs. 21.3%). Testing HIV(SARS-CoV-2) and MLV(HCV) pseudoviruses against antiretroviral drugs showed interference by integrase inhibitors (specifically, dolutegravir). Isolating IgG from serum removed the interference by residual drugs. Retrovirus-based assays are therefore unsuitable for testing individuals receiving integrase inhibitors. Protective immunity to viruses has likely been over-reported in HIV prevalent populations. Retroviral pseudotype-based virus neutralisation assays are widely used to estimate functional immunity, but may be unsuitable for testing human immunodeficiency virus (HIV)-infected individuals receiving integrase inhibitor treatment. We evaluated these assays for measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus (HCV) neutralisation in people living with HIV. SARS-CoV-2 neutralisation was assessed using HIV-based SARS-CoV-2 pseudoviruses in sera from a longitudinal Malawian cohort (n = 1,876), detecting neutralisation across timepoints in 10.5-54.5% of HIV-uninfected vs. 85.5-93.9% of HIV-infected participants (n = 96). HIV-infected sera were re-tested using vesicular stomatitis virus (VSV)-based SARS-CoV-2 pseudoviruses, estimating seroprevalence at 5.6-65.2%, suggesting HIV-based assays overestimate neutralisation. HIV-based VSV-glycoprotein(G) pseudoviruses confirmed non-specific inhibition in 75.0-87.9% of HIV-infected participants. HCV neutralisation was assessed in UK-based HCV patients (n = 100, n = 90 HIV-infected) using murine leukaemia virus (MLV)-based HCV pseudoviruses. Non-HCV-specific inhibition was detected in integrase inhibitor recipients. Median neutralisation of MLV(HCV) pseudoviruses was higher in integrase inhibitor recipients (71.8% vs. 21.3%). Testing HIV(SARS-CoV-2) and MLV(HCV) pseudoviruses against antiretroviral drugs showed interference by integrase inhibitors (specifically, dolutegravir). Isolating IgG from serum removed the interference by residual drugs. Retrovirus-based assays are therefore unsuitable for testing individuals receiving integrase inhibitors. Protective immunity to viruses has likely been over-reported in HIV prevalent populations. Abstract Retroviral pseudotype-based virus neutralisation assays are widely used to estimate functional immunity, but may be unsuitable for testing human immunodeficiency virus (HIV)-infected individuals receiving integrase inhibitor treatment. We evaluated these assays for measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus (HCV) neutralisation in people living with HIV. SARS-CoV-2 neutralisation was assessed using HIV-based SARS-CoV-2 pseudoviruses in sera from a longitudinal Malawian cohort (n = 1,876), detecting neutralisation across timepoints in 10.5–54.5% of HIV-uninfected vs. 85.5–93.9% of HIV-infected participants (n = 96). HIV-infected sera were re-tested using vesicular stomatitis virus (VSV)-based SARS-CoV-2 pseudoviruses, estimating seroprevalence at 5.6–65.2%, suggesting HIV-based assays overestimate neutralisation. HIV-based VSV-glycoprotein(G) pseudoviruses confirmed non-specific inhibition in 75.0-87.9% of HIV-infected participants. HCV neutralisation was assessed in UK-based HCV patients (n = 100, n = 90 HIV-infected) using murine leukaemia virus (MLV)-based HCV pseudoviruses. Non-HCV-specific inhibition was detected in integrase inhibitor recipients. Median neutralisation of MLV(HCV) pseudoviruses was higher in integrase inhibitor recipients (71.8% vs. 21.3%). Testing HIV(SARS-CoV-2) and MLV(HCV) pseudoviruses against antiretroviral drugs showed interference by integrase inhibitors (specifically, dolutegravir). Isolating IgG from serum removed the interference by residual drugs. Retrovirus-based assays are therefore unsuitable for testing individuals receiving integrase inhibitors. Protective immunity to viruses has likely been over-reported in HIV prevalent populations. |
| ArticleNumber | 28580 |
| Author | Ho, Antonia McCormack, Mhairi J. Thomson, Emma C. Asamaphan, Patawee Davis, Chris Kasenda, Stephen Banda, Louis Willett, Brian J. Szemiel, Agnieszka M. Crampin, Amelia Hughes, Ellen C. Amoah, Abena S. |
| Author_xml | – sequence: 1 givenname: Mhairi J. surname: McCormack fullname: McCormack, Mhairi J. email: m.mccormack.1@research.gla.ac.uk organization: Medical Research Council, University of Glasgow Centre for Virus Research – sequence: 2 givenname: Patawee surname: Asamaphan fullname: Asamaphan, Patawee organization: Medical Research Council, University of Glasgow Centre for Virus Research – sequence: 3 givenname: Ellen C. surname: Hughes fullname: Hughes, Ellen C. organization: Medical Research Council, University of Glasgow Centre for Virus Research, Department of Livestock and One Health, Institute of infection, veterinary and ecological sciences, University of Liverpool – sequence: 4 givenname: Louis surname: Banda fullname: Banda, Louis organization: Malawi Epidemiology and Intervention Research Unit (MEIRU) – sequence: 5 givenname: Stephen surname: Kasenda fullname: Kasenda, Stephen organization: Malawi Epidemiology and Intervention Research Unit (MEIRU) – sequence: 6 givenname: Chris surname: Davis fullname: Davis, Chris organization: Medical Research Council, University of Glasgow Centre for Virus Research – sequence: 7 givenname: Agnieszka M. surname: Szemiel fullname: Szemiel, Agnieszka M. organization: Medical Research Council, University of Glasgow Centre for Virus Research – sequence: 8 givenname: Amelia surname: Crampin fullname: Crampin, Amelia organization: Malawi Epidemiology and Intervention Research Unit (MEIRU), London School of Hygiene and Tropical Medicine, School of Health and Wellbeing, University of Glasgow – sequence: 9 givenname: Abena S. surname: Amoah fullname: Amoah, Abena S. organization: Malawi Epidemiology and Intervention Research Unit (MEIRU), London School of Hygiene and Tropical Medicine, Leiden University Medical Center – sequence: 10 givenname: Emma C. surname: Thomson fullname: Thomson, Emma C. organization: Medical Research Council, University of Glasgow Centre for Virus Research, London School of Hygiene and Tropical Medicine – sequence: 11 givenname: Antonia surname: Ho fullname: Ho, Antonia organization: Medical Research Council, University of Glasgow Centre for Virus Research – sequence: 12 givenname: Brian J. surname: Willett fullname: Willett, Brian J. organization: Medical Research Council, University of Glasgow Centre for Virus Research |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40764781$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kstu1TAQhiNUREvpC7BAkdiwCfgaxyuEKi6VKiEhWFuOPUl9lGMH2znSeY8-MD4npRcWeOOR_c0_v8fzsjrxwUNVvcboPUa0-5AY5rJrEOENxrQljXhWnRHEeEMoISeP4tPqIqUNKosTybB8UZ0yJFomOnxW3f6AHMPOxSU1vU5g6znBYkPezyU-ntcelhz15JLOLvhap6T3qQ47iJCy2-oMD4jzY61NdjuX97XzdYKo6yGGbT3rmJ1xs_Y51REMFKbAzmcYY6lcohvXuxxielU9H_SU4OJuP69-ffn88_Jbc_3969Xlp-vGMMly01oAsHbA1CCBWqRx12uJLIahH6CnWBpKLR4GrluNCeVEG1quOKWcCi7peXW16tqgN2qO5S1xr4J26ngQ4qiOpidQDHHEpWwlIcB6UpKL3mCBdgIo6w5aH1eteem3YA34Q0OeiD698e5GjWGnijHChcRF4d2dQgy_l9JatXXJwDRpD2FJqlRspZSiYwV9-w-6CUv0pVdHqkOMiYOlN48t3Xv5-_sFICtgYkgpwnCPYKQOU6bWKVNlytRxypQoSXRNSgX2I8SH2v_J-gOYsdlQ |
| Cites_doi | 10.1056/NEJMoa2102214 10.1038/s41591-021-01377-8 10.1038/s41591-021-01285-x 10.1038/s41564-022-01143-7 10.1016/j.virusres.2015.12.019 10.1093/infdis/jiac332 10.3389/fimmu.2022.981693 10.3390/mps1010008 10.1080/22221751.2021.1925163 10.1126/science.abm3425 10.1016/S1473-3099(22)00596-5 10.1186/s13029-014-0027-x 10.1038/s41564-022-01262-1 10.1002/rmv.1963 10.1002/jmv.28543 10.1073/pnas.0908074106 10.1371/journal.pone.0248348 10.1128/JVI.01711-08 10.1016/S0140-6736(21)01290-3 10.1016/j.ijid.2023.10.020 10.1016/j.vaccine.2015.12.006 10.1016/j.bsheal.2021.12.006 10.1038/s41467-022-35768-3 10.1038/s41596-020-0394-5 10.1084/jem.20021756 10.1093/jac/dky465 10.1016/S2666-5247(21)00267-6 10.1038/s41596-021-00536-y 10.1371/journal.ppat.1009958 10.3390/v14061221 10.1371/journal.ppat.1010022 10.1136/gut.2010.217166 10.1038/s41591-021-01540-1 10.3390/v14081716 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025 2025. The Author(s). The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2025 2025 |
| Copyright_xml | – notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2025 2025 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-025-11362-7 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Database Suite (ProQuest) Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Collection (ProQuest) ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Science Database Biological Science Database (ProQuest) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ: Directory of Open Access Journal (DOAJ) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 13 |
| ExternalDocumentID | oai_doaj_org_article_40505996922e4b2593235fde387e3489 PMC12325791 40764781 10_1038_s41598_025_11362_7 |
| Genre | Journal Article |
| GeographicLocations | United Kingdom--UK Malawi |
| GeographicLocations_xml | – name: United Kingdom--UK – name: Malawi |
| GrantInformation_xml | – fundername: Medical Research Council grantid: MC_UU_00034/6 funderid: https://doi.org/10.13039/501100000265 – fundername: Wellcome Trust grantid: 217073/Z/19/Z funderid: https://doi.org/10.13039/100010269 – fundername: Medical Research Council grantid: MC_UU_00034/6 – fundername: Wellcome Trust grantid: 217073/Z/19/Z |
| GroupedDBID | 0R~ 4.4 53G 5VS 7X7 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD AARCD AASML ABDBF ABUWG ACGFS ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AFPKN ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M1P M2P M7P M~E NAO OK1 PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AAYXX CITATION PUEGO CGR CUY CVF ECM EIF NPM 3V. 7XB 88A 8FK K9. M48 PKEHL PQEST PQUKI Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c494t-6deeeddf13c07060a18ba90d1efbfeb319c33d1ff5a6a12352ac3fbf533537593 |
| IEDL.DBID | DOA |
| ISSN | 2045-2322 |
| IngestDate | Wed Aug 27 01:25:41 EDT 2025 Thu Aug 21 18:29:59 EDT 2025 Fri Sep 05 15:31:46 EDT 2025 Wed Aug 06 17:19:45 EDT 2025 Mon Aug 11 01:32:20 EDT 2025 Wed Sep 10 23:58:53 EDT 2025 Wed Aug 06 16:36:34 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Pseudovirus assay HIV Integrase inhibitors Interference |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c494t-6deeeddf13c07060a18ba90d1efbfeb319c33d1ff5a6a12352ac3fbf533537593 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/40505996922e4b2593235fde387e3489 |
| PMID | 40764781 |
| PQID | 3236804479 |
| PQPubID | 2041939 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_40505996922e4b2593235fde387e3489 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12325791 proquest_miscellaneous_3236999784 proquest_journals_3236804479 pubmed_primary_40764781 crossref_primary_10_1038_s41598_025_11362_7 springer_journals_10_1038_s41598_025_11362_7 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-08-05 |
| PublicationDateYYYYMMDD | 2025-08-05 |
| PublicationDate_xml | – month: 08 year: 2025 text: 2025-08-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2025 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | C Davis (11362_CR9) 2021; 17 11362_CR37 EC Wall (11362_CR7) 2021; 397 SA Madhi (11362_CR19) 2021; 384 11362_CR39 11362_CR38 FL Cosset (11362_CR32) 2009; 83 HP Feng (11362_CR30) 2018; 74 J Nie (11362_CR14) 2020; 15 P Rozo-Lopez (11362_CR36) 2022; 14 S Hu (11362_CR11) 2022; 14 S Feng (11362_CR3) 2021; 27 S Wang (11362_CR13) 2022; 4 WY Tsai (11362_CR15) 2021; 10 SN Neerukonda (11362_CR20) 2021; 16 KR Bewley (11362_CR25) 2021; 16 N Mishra (11362_CR22) 2021; 17 Y Fong (11362_CR5) 2022; 7 M Manali (11362_CR24) 2022; 227 11362_CR40 11362_CR41 EC Thomson (11362_CR34) 2011; 60 PB Gilbert (11362_CR4) 2022; 375 BJ Willett (11362_CR10) 2022; 7 11362_CR27 11362_CR29 DS Khoury (11362_CR1) 2021; 27 J Luczkowiak (11362_CR33) 2016; 213 TT Nguyen (11362_CR28) 2014; 9 L Banda (11362_CR23) 2023; 137 N Logan (11362_CR35) 2016; 34 SA Madhi (11362_CR18) 2023; 23 CK Wibmer (11362_CR17) 2021; 27 Y Fong (11362_CR6) 2023; 14 F Ferrara (11362_CR12) 2018; 1 D Cromer (11362_CR2) 2022; 3 L D’Apice (11362_CR8) 2022; 13 Q Li (11362_CR16) 2018; 28 B Bartosch (11362_CR26) 2003; 197 11362_CR31 E De La Torre-Tarazona (11362_CR21) 2023; 95 |
| References_xml | – volume: 384 start-page: 1885 year: 2021 ident: 11362_CR19 publication-title: N Engl. J. Med. doi: 10.1056/NEJMoa2102214 – volume: 27 start-page: 1205 year: 2021 ident: 11362_CR1 publication-title: Nat. Med. doi: 10.1038/s41591-021-01377-8 – volume: 27 start-page: 622 year: 2021 ident: 11362_CR17 publication-title: Nat. Med. doi: 10.1038/s41591-021-01285-x – volume: 7 start-page: 1161 year: 2022 ident: 11362_CR10 publication-title: Nat. Microbiol. doi: 10.1038/s41564-022-01143-7 – volume: 213 start-page: 224 year: 2016 ident: 11362_CR33 publication-title: Virus Res. doi: 10.1016/j.virusres.2015.12.019 – volume: 227 start-page: 40 year: 2022 ident: 11362_CR24 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiac332 – ident: 11362_CR39 – ident: 11362_CR37 – volume: 13 start-page: 981693 year: 2022 ident: 11362_CR8 publication-title: Front. Immunol. doi: 10.3389/fimmu.2022.981693 – volume: 1 start-page: 1 year: 2018 ident: 11362_CR12 publication-title: Methods Protoc. doi: 10.3390/mps1010008 – ident: 11362_CR31 – volume: 10 start-page: 894 year: 2021 ident: 11362_CR15 publication-title: Emerg. Microbes Infect. doi: 10.1080/22221751.2021.1925163 – volume: 375 start-page: 43 year: 2022 ident: 11362_CR4 publication-title: Scienc doi: 10.1126/science.abm3425 – volume: 23 start-page: 295 year: 2023 ident: 11362_CR18 publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(22)00596-5 – volume: 9 start-page: 27 year: 2014 ident: 11362_CR28 publication-title: Source Code Biol. Med. doi: 10.1186/s13029-014-0027-x – ident: 11362_CR41 – volume: 7 start-page: 1996 year: 2022 ident: 11362_CR5 publication-title: Nat. Microbiol. doi: 10.1038/s41564-022-01262-1 – volume: 28 start-page: 1 year: 2018 ident: 11362_CR16 publication-title: Rev. Med. Virol. doi: 10.1002/rmv.1963 – volume: 95 start-page: e28543 year: 2023 ident: 11362_CR21 publication-title: J. Med. Virol. doi: 10.1002/jmv.28543 – ident: 11362_CR29 doi: 10.1073/pnas.0908074106 – volume: 16 start-page: e0248348 year: 2021 ident: 11362_CR20 publication-title: PLoS One doi: 10.1371/journal.pone.0248348 – volume: 83 start-page: 3228 year: 2009 ident: 11362_CR32 publication-title: J. Virol. doi: 10.1128/JVI.01711-08 – volume: 397 start-page: 2331 year: 2021 ident: 11362_CR7 publication-title: Lancet doi: 10.1016/S0140-6736(21)01290-3 – volume: 137 start-page: 118 year: 2023 ident: 11362_CR23 publication-title: Int. J. Infect. Dis. doi: 10.1016/j.ijid.2023.10.020 – volume: 34 start-page: 814 year: 2016 ident: 11362_CR35 publication-title: Vaccine doi: 10.1016/j.vaccine.2015.12.006 – volume: 4 start-page: 38 year: 2022 ident: 11362_CR13 publication-title: Biosaf. Health doi: 10.1016/j.bsheal.2021.12.006 – ident: 11362_CR38 – volume: 14 start-page: 331 year: 2023 ident: 11362_CR6 publication-title: Nat. Commun. doi: 10.1038/s41467-022-35768-3 – volume: 15 start-page: 3699 year: 2020 ident: 11362_CR14 publication-title: Nat. Protoc. doi: 10.1038/s41596-020-0394-5 – volume: 197 start-page: 633 year: 2003 ident: 11362_CR26 publication-title: J. Exp. Med. doi: 10.1084/jem.20021756 – volume: 74 start-page: 710 year: 2018 ident: 11362_CR30 publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dky465 – volume: 3 start-page: e52 year: 2022 ident: 11362_CR2 publication-title: Lancet Microbe doi: 10.1016/S2666-5247(21)00267-6 – volume: 16 start-page: 3114 year: 2021 ident: 11362_CR25 publication-title: Nat. Protoc. doi: 10.1038/s41596-021-00536-y – volume: 17 start-page: e1009958 year: 2021 ident: 11362_CR22 publication-title: PLOS Pathog doi: 10.1371/journal.ppat.1009958 – volume: 14 start-page: 1221 year: 2022 ident: 11362_CR36 publication-title: Viruses doi: 10.3390/v14061221 – volume: 17 start-page: e1010022 year: 2021 ident: 11362_CR9 publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1010022 – volume: 60 start-page: 837 year: 2011 ident: 11362_CR34 publication-title: Gut doi: 10.1136/gut.2010.217166 – ident: 11362_CR40 – volume: 27 start-page: 2032 year: 2021 ident: 11362_CR3 publication-title: Nat. Med. doi: 10.1038/s41591-021-01540-1 – volume: 14 start-page: 8 year: 2022 ident: 11362_CR11 publication-title: Viruses doi: 10.3390/v14081716 – ident: 11362_CR27 |
| SSID | ssj0000529419 |
| Score | 2.4638083 |
| Snippet | Retroviral pseudotype-based virus neutralisation assays are widely used to estimate functional immunity, but may be unsuitable for testing human... Abstract Retroviral pseudotype-based virus neutralisation assays are widely used to estimate functional immunity, but may be unsuitable for testing human... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 28580 |
| SubjectTerms | 631/1647 631/250 631/326/596 Adult Antibodies Antibodies, Neutralizing - blood Antibodies, Neutralizing - immunology Antibodies, Viral - blood Antibodies, Viral - immunology Antiretroviral agents Confidence intervals Coronaviruses COVID-19 COVID-19 - blood COVID-19 - immunology COVID-19 - virology Female Glycoproteins Hepacivirus - immunology Hepatitis C Hepatitis C - immunology HIV HIV Infections - blood HIV Infections - drug therapy HIV Infections - immunology HIV Infections - virology Human immunodeficiency virus Humanities and Social Sciences Humans Immunity Immunoglobulin G Inhibitors Integrase Integrase inhibitors Integrase Inhibitors - therapeutic use Interference Leukemia Male Mann-Whitney U test Middle Aged multidisciplinary Neutralization Tests - methods Pseudovirus assay Pyridones Retroviridae - immunology SARS-CoV-2 - immunology Science Science (multidisciplinary) Serology Severe acute respiratory syndrome coronavirus 2 Statistical significance Stomatitis |
| SummonAdditionalLinks | – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkLKu-0BRmJG0RNYju2TxUgqgoJDohKe7Mc26G5ZLeb5ND_0R_cGce7q-V1i2Kv5OzMeL55E_JOlMpb1UoQJOlz3tQ-b9rC5aJw1kuua-7Q3_Hte31xyb8uxCI53IaUVrm5E-NF7ZcOfeSnrGK1KjiX-mx1nePUKIyuphEa98mDEpAIjm6QC7n1sWAUi5c61coUTJ0OoK-wpqwSOQ4zAXC5p49i2_6_Yc0_UyZ_i5tGdXR-SB4nHEk_zoR_Qu6F_il5OE-WvHlGbn-EEZ0F62nIUVF5uhrCBBYomJ2exve0D1N0c8z5PBRQtL0ZKKZ0YucNQLJhtwXOQLEEAidN0K6nODyCYmkKXdmUmN2PA4XrM3TooqCpDcUQ4Omqazoc6vOcXJ5_-fn5Ik8DGHLHNR_z2gdQob4tmSuwy44tVWN14cvQNi1Y4aV2jPmybYWtLRbdVtYxWAIIKZgUmr0gB_2yD68IBTNGFOhoYcxyKV0jilp7LZgWjru2ycj7DRnMau6zYWJ8nCkzE80A0UwkmpEZ-YSU2u7EHtnxxXL9yySRMxyH9IE5p6sq8AbMPGAh0frAlAyMK52Rkw2dTRLcwezYLCNvt8sgchhHsX1YTvMewNVS8Yy8nNliexKwj2P1bkbUHsPsHXV_pe-uYltvBLdCavjphw1v7c717__i6P-fcUweVcjumOUiTsjBuJ7Ca8BRY_MmCssdYt8f6Q priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKERIXRHk1UCojcYOIJLZj-1hWVBUSHBCVerP8Cs0lu9okh_4PfjAzTrLV0nLgFsUTaZQZe74Zz4OQ96JUwapGwkaSIeeuDrlrCp-Lwtsgua65x3jHt-_1xSX_eiWuDki11MKkpP3U0jId00t22KceDA0Wg1UixykkgAofkIdKMoFavapXu7gK3lzxUs_1MQVT93y6Z4NSq_778OXdNMm_7kqTCTp_Sp7M2JGeTdwekYPYPSOPpmmSN8_J7x9xwADBduxzNE6Bbvo4gtcJrmag6T3t4phCG1MODwXkbG96immc2G0D0Gu8JQEeKJY94HQJ2nYUB0ZQLEehGzsnY3dDT-HIjC2GJejceqKP8HTduhYH-bwgl-dffq4u8nnoQu655kNehwhmMzQl8wV21rGlclYXoYyNa8DzLrVnLJRNI2xtsdC2sp7BEsBGwaTQ7CU57NZdPCYUXBdRYHCFMcul9E4UtQ5aMC08943LyIdFDGYz9dYw6U6cKTMJzYDQTBKakRn5jJLaUWJf7PRivf1lZj0xHAfzgQunqypyB64dAw6bEJmSkXGlM3KyyNnMm7U3QFOrgnMJy-92y7DN8O7EdnE9TjSApaXiGXk1qcWOE_CJU8VuRtSewuyxur_StdeplTcCWiE1fPpx0a1bvv79L17_H_kb8rhC9cdMF3FCDoftGN8Clhrcado8fwAQUR23 priority: 102 providerName: Springer Nature |
| Title | Retrovirus-based pseudotyped virus neutralisation assays overestimate neutralising activity in sera from participants receiving integrase inhibitors |
| URI | https://link.springer.com/article/10.1038/s41598-025-11362-7 https://www.ncbi.nlm.nih.gov/pubmed/40764781 https://www.proquest.com/docview/3236804479 https://www.proquest.com/docview/3236999784 https://pubmed.ncbi.nlm.nih.gov/PMC12325791 https://doaj.org/article/40505996922e4b2593235fde387e3489 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBZtSqGX0necposKvbUmtiVZ1nGzJISFhpI2sDchSzLxxVli-5D_0R-cGcm7yfZBLz3tImlh0MzsfDOaByGfRF45UzUSFEm6lNelS-sms6nIrHGSq5JbjHd8PS_PLvlyJVYPRn1hTlhsDxwv7ojjqDUA5aooPK8BrLOCicZ5VknPeBVK9zKVPXCmYlfvQvFcTVUyGauOerBUWE1WiBTHmACs3LFEoWH_n1Dm78mSv7yYBkN0-oI8nxAknUfKX5JHvntFnsaZkrevyc8LP2CY4GbsUzRRjq57P4LvCQ6no2Gddn4MAY6YyUMBP5vbnmIyJ_bcAAzr748ADRSLH3DGBG07imMjKBal0LWZUrK7oafwx-lbDE7QqQFF7-HbVVu3OM7nDbk8PfmxOEun0Qup5YoPaek8GE_X5Mxm2F_H5FVtVOZy39QN-N-5soy5vGmEKQ2W2xbGMtgC8CiYBCa9JXvddef3CQUHRmQYYmHMcCltLbJSOSWYEpbbpk7I5w0b9Dp22NDhZZxVOjJNA9N0YJqWCTlGTm1PYnfssAAyoyeZ0f-SmYQcbvisJ5XtNZwpq4xzCdsft9ugbPiCYjp_PcYzgKhlxRPyLorFlhLwjEPdbkKqHYHZIXV3p2uvQkNvhLVCKvjpl41s3dP197s4-B938Z48K1ApMAtGHJK94Wb0HwBnDfWMPJYrOSNP5vPl9yV8Hp-cf7uA1UW5mAV1uwOEbitX |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamTgheEHcCA4wETxAtie04fpgQg00d2yo0bdLejGM7rC9paVqh_g9-D7-Nc5ykVbm97S2KXcnpOcfnfj5CXom0cKaoJAiSdDEvcxeXVWJjkVjjJFc5txjvOB3lwwv-6VJcbpGffS8MllX2d2K4qN3EYox8l2UsLxLOpXo3_RYjahRmV3sIDdNBK7i9MGKsa-w49svv4MI1e0cfgd6vs-zw4PzDMO5QBmLLFZ_HufOgJ1yVMpvgKBmTFqVRiUt9VVbgaqbKMubSqhImN9hZmhnLYAnsJMGkwGFMoAK2OQZQBmR7_2D0-WwV5cE8Gk9V162TsGK3AY2JXW2ZiBFOBczbDY0YgAP-Zu3-WbT5W-Y2KMTDO-R2Z8nS9y3r3SVbvr5HbrTYlsv75MeZn2O4YrZoYlSVjk4bvwAfGBxfR8N7WvtFCLS0FUUU7HizbCgWleLsD7Cl_XoLnIFiEwZiXdBxTRG-gmJzDJ2arjS8njcULnA_xiAJ7QZhNB6ersblGGGFHpCLayHOQzKoJ7V_TCg4UiLBUA9jhktpS5HkyinBlLDcVmVE3vRk0NN20ocOGXpW6JZoGoimA9G0jMg-Umq1E6d0hxeT2VfdCb3mCBMIDqXKMs9LcDSBiUXlPCukZ7xQEdnp6ay7q6PRa0aPyMvVMgg9ZnJM7SeLdg9Y9rLgEXnUssXqJOChh_7hiBQbDLNx1M2VenwVBoujeS2kgp--7Xlrfa5__xdP_v8ZL8jN4fnpiT45Gh0_JbcyZH2suRE7ZDCfLfwzsOrm5fNOdCj5ct3S-gvPP2Tn |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamTSBeEPcFBhgJniBqEttx_DAhxlZtDKppYtLegmM7rC9paVqh_g9-Fb-KcxynVbm97S2KXcnpOT73cz5CXoq0sLqoJVwkaWNe5Tau6sTEIjHaSq5ybjDe8WmUH1_wD5ficov87HthsKyyl4leUNuJwRj5gGUsLxLOpRrUoSzi7HD4dvotRgQpzLT2cBo6wCzYfT9uLDR5nLrld3Dn2v2TQ6D9qywbHn1-fxwHxIHYcMXncW4d6Axbp8wkOFZGp0WlVWJTV1c1uJ2pMozZtK6FzjV2mWbaMFgCm0kwKXAwE6iDHQlaHxzBnYOj0dn5KuKDOTWeqtC5k7Bi0IL2xA63TMQIrQKm7oZ29CACf7N8_yzg_C2L65Xj8A65Haxa-q5jw7tkyzX3yI0O53J5n_w4d3MMXcwWbYxq09Jp6xbgD4MTbKl_Txu38EGXrrqIgk2vly3FAlOcAwJ2tVtvgTNQbMhA3As6bihCWVBslKFTHcrEm3lLQZi7MQZMaBiK0Tp4uhpXY4QYekAuroU4D8l2M2ncLqHgVIkEwz6MaS6lqUSSK6sEU8JwU1cRed2ToZx2Uz9Kn61nRdkRrQSilZ5opYzIAVJqtRMndvsXk9nXMgiAkiNkIDiXKsscr8DpBIYWtXWskI7xQkVkr6dzGcRIW66ZPiIvVssgADCroxs3WXR7wMqXBY_Io44tVicBb933Ekek2GCYjaNurjTjKz9kHE1tIRX89E3PW-tz_fu_ePz_z3hObsKtLT-ejE6fkFsZcj6W34g9sj2fLdxTMPDm1bNwcyj5ct2X9Rdrh2kr |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Retrovirus-based+pseudotyped+virus+neutralisation+assays+overestimate+neutralising+activity+in+sera+from+participants+receiving+integrase+inhibitors&rft.jtitle=Scientific+reports&rft.au=McCormack%2C+Mhairi+J&rft.au=Asamaphan%2C+Patawee&rft.au=Hughes%2C+Ellen+C&rft.au=Banda%2C+Louis&rft.date=2025-08-05&rft.eissn=2045-2322&rft.volume=15&rft.issue=1&rft.spage=28580&rft_id=info:doi/10.1038%2Fs41598-025-11362-7&rft_id=info%3Apmid%2F40764781&rft.externalDocID=40764781 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |